Formpipe

Formpipe

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Formpipe - Positive margin trend, improved ACV

07 maj 2026

  • Strong margins (19% adj. EBIT margin), improved ACV
  • We raise '26e/'27e/'28e EBIT by 20%/6%/5% on lower costs
  • Positive margin trajectory to continue

Sequential progress

For the third consecutive quarter, Formpipe (soon to be renamed Lasernet) achieved better-than-expected cost control, driven by several cost-saving measures implemented over the past 12 months. The adj. EBIT margin was 19% (ABGSCe 12%), a significant improvement from 1% in Q1'25 (proforma). Meanwhile, ACV bounced back to SEK 6m (vs. SEK 8m in Q1'25) after a weak Q4 (SEK 2m), chiefly driven by continued momentum in Microsoft Dynamics (63% of ARR), while improved activity with Temenos remains to be seen. The fact that the company has managed to maintain solid sales progress while reducing costs demonstrates that previous cost levels were too high and that its partner-led sales model is effective.

Positive earnings revisions

The cost base is now in much better shape, and we currently see no need for increased investment in the near term. This means that operational leverage should remain high over the coming quarters, leading us to expect an adj. EBIT margin of 14% in 2026. While we make minor adjustments to our sales estimates, we increase '26e/'27e/'28e adj. EBIT by 20%/6%/5% based on lower cost assumptions.

A profitable software company with stable cash flow

The value proposition has changed considerably since the sale of the public business. Today, Formpipe is a global software company with >75% recurring revenue that is growing ~8% organically per year and with prospects for further margin improvements. Also, the cash profile is much more stable throughout the year (previously a significant share of invoicing occurred in Q4). The approved extraordinary dividends following the public sale corresponds to SEK 14/share. Based on the current market cap, the stock is trading at 30x/24x '26e/'27e EV/EBIT.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys
2026-08-21 Generic - Investing while growing Generic Analys
2026-08-21 Impact Coatings - A quarter driven by Coating Ser... Impact Coat.. Analys
2026-08-21 Skolon - Sweden profitability gains continue Skolon Analys
2026-08-21 I-tech - Strongest quarter on record I-tech Analys
2026-08-20 Tempest Security - Patrols below plan Tempest Sec.. Analys
2026-08-20 Tempest Security - Progress made but expectations... Tempest Sec.. Analys
2026-08-20 Ascelia Pharma - Still alive: Fighting to reverse... Ascelia Pharma Analys
2026-08-20 Clavister - Defence drives record quarter Clavister Analys
2026-08-20 Catella - Q2 softer than expected, but underlying... Catella Analys
2026-08-20 Generic - Volumes continue to grow Generic Analys
2026-08-19 SinterCast - Past the trough, but recovery pace u... SinterCast Analys
2026-08-19 Xplora Technologies - EBITDA -13% on soft senior ... Xplora Tech.. Analys